Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares saw an uptick in trading volume on Tuesday . 2,549,469 shares changed hands during trading, an increase of 1,723% from the previous session’s volume of 139,874 shares.The stock last traded at $0.87 and had previously closed at $0.84.
Several brokerages have weighed in on CYCC. Zacks Investment Research raised Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Friday, November 16th. ValuEngine downgraded Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $5.63.
A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC lifted its position in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 76,500 shares during the quarter. Renaissance Technologies LLC owned 0.76% of Cyclacel Pharmaceuticals worth $130,000 as of its most recent SEC filing. Institutional investors own 5.69% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cyclacel Pharmaceuticals (CYCC) Sees Unusually-High Trading Volume” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/4199574/cyclacel-pharmaceuticals-cycc-sees-unusually-high-trading-volume.html.
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Further Reading: Yield Curve
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.